Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer. Naz, S., Ahmad, S., Ghafoor, F., Butt, N., S., Akhtar, M., W., & Naz Ahmad, S., Ghafoor, F., Butt, N. S., & Akhtar, M. W., S. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 14(2):69-71, 2004. abstract bibtex Objective: To record the levels of PSA in the sera of prostate cancer (CaP) and benign prostatic hyperplasia (BPH) cases. Free PSA/total PSA as percentage was also calculated in order to evaluate its utility in differentially diagnosing BPH and CaP. Design: A cross-sectional, case control study. Place and Duration of Study: Shaikh Zayed Hospital and Mayo Hospital, Lahore from August 2002 to March 2003. Materials and Methods: A group of 108 male subjects, including one-third of each of biopsy-confirmed prostate cancer cases, BPH cases and asymptomatic controls of matching age were studied. PSA and Free PSA were determined by ELISA using commercially available assay kits. Results: Mean PSA was found to be highest in CaP cases (41.9 ± 38.7 ng/ml), lower in the BPH cases (13.5±10.5 ng/ml), while it was lowest in the control subjects (5.7 ± 4.4 ng/ml). Moreover, it was observed that a majority of the CaP cases had serum PSA >20 ng/ml, 50% of BPH cases had serum PSA in the 'gray zone' (4.1-20 ng/ml), while majority of controls had serum PSA in the 'normal' range (0 - 4 ng/ml). Using a free-PSA "cut-off" of 18% to differentiate between benign and malignant prostate enlargement, it was found that 80% of the CaP cases had F/T% <18, while 75% of the BPH cases had F/T%> 18. The percent free-PSA test to differentially diagnose BPH and CaP in the 'gray zone' was found to have a sensitivity of 86% and a specificity of 94%. Conclusion: Using a cutoff of 18%, the free-PSA test significantly improved the differential diagnosis of BPH and CaP in the 'gray zone' as compared to the use of total PSA alone in the study group.
@article{
title = {Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.},
type = {article},
year = {2004},
keywords = {Benign hyperplasia,Free PSA,Prostate cancer,Prostate specific antigen (PSA)},
pages = {69-71},
volume = {14},
id = {fe45e05b-61a5-3eba-a5b1-133bb67ab146},
created = {2021-08-31T15:29:47.409Z},
file_attached = {true},
profile_id = {49efd9d1-b84a-3562-b8db-36e64ac7ba81},
last_modified = {2021-08-31T15:47:15.264Z},
read = {false},
starred = {false},
authored = {true},
confirmed = {true},
hidden = {false},
citation_key = {naz2004free},
source_type = {article},
folder_uuids = {4cfcf1ef-e8a1-481b-9768-92f271f79e14,61cd76d5-8771-4789-bd8b-c373e7bef009},
private_publication = {false},
abstract = {Objective: To record the levels of PSA in the sera of prostate cancer (CaP) and benign prostatic hyperplasia (BPH) cases. Free PSA/total PSA as percentage was also calculated in order to evaluate its utility in differentially diagnosing BPH and CaP. Design: A cross-sectional, case control study. Place and Duration of Study: Shaikh Zayed Hospital and Mayo Hospital, Lahore from August 2002 to March 2003. Materials and Methods: A group of 108 male subjects, including one-third of each of biopsy-confirmed prostate cancer cases, BPH cases and asymptomatic controls of matching age were studied. PSA and Free PSA were determined by ELISA using commercially available assay kits. Results: Mean PSA was found to be highest in CaP cases (41.9 ± 38.7 ng/ml), lower in the BPH cases (13.5±10.5 ng/ml), while it was lowest in the control subjects (5.7 ± 4.4 ng/ml). Moreover, it was observed that a majority of the CaP cases had serum PSA >20 ng/ml, 50% of BPH cases had serum PSA in the 'gray zone' (4.1-20 ng/ml), while majority of controls had serum PSA in the 'normal' range (0 - 4 ng/ml). Using a free-PSA "cut-off" of 18% to differentiate between benign and malignant prostate enlargement, it was found that 80% of the CaP cases had F/T% <18, while 75% of the BPH cases had F/T%> 18. The percent free-PSA test to differentially diagnose BPH and CaP in the 'gray zone' was found to have a sensitivity of 86% and a specificity of 94%. Conclusion: Using a cutoff of 18%, the free-PSA test significantly improved the differential diagnosis of BPH and CaP in the 'gray zone' as compared to the use of total PSA alone in the study group.},
bibtype = {article},
author = {Naz, Saima and Ahmad, Sarah and Ghafoor, Farkhanda and Butt, Nadeem Shafique and Akhtar, M. Waheed and Naz Ahmad, S., Ghafoor, F., Butt, N. S., & Akhtar, M. W., S},
journal = {Journal of the College of Physicians and Surgeons--Pakistan: JCPSP},
number = {2}
}
Downloads: 0
{"_id":"5hg5g8ETRjn3u9m95","bibbaseid":"naz-ahmad-ghafoor-butt-akhtar-nazahmad-freeandtotalprostatespecificantigeninbenignprostatehyperplasiaandprostatecancer-2004","downloads":0,"creationDate":"2017-11-04T12:35:01.497Z","title":"Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.","author_short":["Naz, S.","Ahmad, S.","Ghafoor, F.","Butt, N., S.","Akhtar, M., W.","Naz Ahmad, S., Ghafoor, F., Butt, N. S., & Akhtar, M. W., S."],"year":2004,"bibtype":"article","biburl":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81","bibdata":{"title":"Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.","type":"article","year":"2004","keywords":"Benign hyperplasia,Free PSA,Prostate cancer,Prostate specific antigen (PSA)","pages":"69-71","volume":"14","id":"fe45e05b-61a5-3eba-a5b1-133bb67ab146","created":"2021-08-31T15:29:47.409Z","file_attached":"true","profile_id":"49efd9d1-b84a-3562-b8db-36e64ac7ba81","last_modified":"2021-08-31T15:47:15.264Z","read":false,"starred":false,"authored":"true","confirmed":"true","hidden":false,"citation_key":"naz2004free","source_type":"article","folder_uuids":"4cfcf1ef-e8a1-481b-9768-92f271f79e14,61cd76d5-8771-4789-bd8b-c373e7bef009","private_publication":false,"abstract":"Objective: To record the levels of PSA in the sera of prostate cancer (CaP) and benign prostatic hyperplasia (BPH) cases. Free PSA/total PSA as percentage was also calculated in order to evaluate its utility in differentially diagnosing BPH and CaP. Design: A cross-sectional, case control study. Place and Duration of Study: Shaikh Zayed Hospital and Mayo Hospital, Lahore from August 2002 to March 2003. Materials and Methods: A group of 108 male subjects, including one-third of each of biopsy-confirmed prostate cancer cases, BPH cases and asymptomatic controls of matching age were studied. PSA and Free PSA were determined by ELISA using commercially available assay kits. Results: Mean PSA was found to be highest in CaP cases (41.9 ± 38.7 ng/ml), lower in the BPH cases (13.5±10.5 ng/ml), while it was lowest in the control subjects (5.7 ± 4.4 ng/ml). Moreover, it was observed that a majority of the CaP cases had serum PSA >20 ng/ml, 50% of BPH cases had serum PSA in the 'gray zone' (4.1-20 ng/ml), while majority of controls had serum PSA in the 'normal' range (0 - 4 ng/ml). Using a free-PSA \"cut-off\" of 18% to differentiate between benign and malignant prostate enlargement, it was found that 80% of the CaP cases had F/T% <18, while 75% of the BPH cases had F/T%> 18. The percent free-PSA test to differentially diagnose BPH and CaP in the 'gray zone' was found to have a sensitivity of 86% and a specificity of 94%. Conclusion: Using a cutoff of 18%, the free-PSA test significantly improved the differential diagnosis of BPH and CaP in the 'gray zone' as compared to the use of total PSA alone in the study group.","bibtype":"article","author":"Naz, Saima and Ahmad, Sarah and Ghafoor, Farkhanda and Butt, Nadeem Shafique and Akhtar, M. Waheed and Naz Ahmad, S., Ghafoor, F., Butt, N. S., & Akhtar, M. W., S","journal":"Journal of the College of Physicians and Surgeons--Pakistan: JCPSP","number":"2","bibtex":"@article{\n title = {Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.},\n type = {article},\n year = {2004},\n keywords = {Benign hyperplasia,Free PSA,Prostate cancer,Prostate specific antigen (PSA)},\n pages = {69-71},\n volume = {14},\n id = {fe45e05b-61a5-3eba-a5b1-133bb67ab146},\n created = {2021-08-31T15:29:47.409Z},\n file_attached = {true},\n profile_id = {49efd9d1-b84a-3562-b8db-36e64ac7ba81},\n last_modified = {2021-08-31T15:47:15.264Z},\n read = {false},\n starred = {false},\n authored = {true},\n confirmed = {true},\n hidden = {false},\n citation_key = {naz2004free},\n source_type = {article},\n folder_uuids = {4cfcf1ef-e8a1-481b-9768-92f271f79e14,61cd76d5-8771-4789-bd8b-c373e7bef009},\n private_publication = {false},\n abstract = {Objective: To record the levels of PSA in the sera of prostate cancer (CaP) and benign prostatic hyperplasia (BPH) cases. Free PSA/total PSA as percentage was also calculated in order to evaluate its utility in differentially diagnosing BPH and CaP. Design: A cross-sectional, case control study. Place and Duration of Study: Shaikh Zayed Hospital and Mayo Hospital, Lahore from August 2002 to March 2003. Materials and Methods: A group of 108 male subjects, including one-third of each of biopsy-confirmed prostate cancer cases, BPH cases and asymptomatic controls of matching age were studied. PSA and Free PSA were determined by ELISA using commercially available assay kits. Results: Mean PSA was found to be highest in CaP cases (41.9 ± 38.7 ng/ml), lower in the BPH cases (13.5±10.5 ng/ml), while it was lowest in the control subjects (5.7 ± 4.4 ng/ml). Moreover, it was observed that a majority of the CaP cases had serum PSA >20 ng/ml, 50% of BPH cases had serum PSA in the 'gray zone' (4.1-20 ng/ml), while majority of controls had serum PSA in the 'normal' range (0 - 4 ng/ml). Using a free-PSA \"cut-off\" of 18% to differentiate between benign and malignant prostate enlargement, it was found that 80% of the CaP cases had F/T% <18, while 75% of the BPH cases had F/T%> 18. The percent free-PSA test to differentially diagnose BPH and CaP in the 'gray zone' was found to have a sensitivity of 86% and a specificity of 94%. Conclusion: Using a cutoff of 18%, the free-PSA test significantly improved the differential diagnosis of BPH and CaP in the 'gray zone' as compared to the use of total PSA alone in the study group.},\n bibtype = {article},\n author = {Naz, Saima and Ahmad, Sarah and Ghafoor, Farkhanda and Butt, Nadeem Shafique and Akhtar, M. Waheed and Naz Ahmad, S., Ghafoor, F., Butt, N. S., & Akhtar, M. W., S},\n journal = {Journal of the College of Physicians and Surgeons--Pakistan: JCPSP},\n number = {2}\n}","author_short":["Naz, S.","Ahmad, S.","Ghafoor, F.","Butt, N., S.","Akhtar, M., W.","Naz Ahmad, S., Ghafoor, F., Butt, N. S., & Akhtar, M. W., S."],"biburl":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81","bibbaseid":"naz-ahmad-ghafoor-butt-akhtar-nazahmad-freeandtotalprostatespecificantigeninbenignprostatehyperplasiaandprostatecancer-2004","role":"author","urls":{},"keyword":["Benign hyperplasia","Free PSA","Prostate cancer","Prostate specific antigen (PSA)"],"metadata":{"authorlinks":{"butt, n":"https://nsbstat.com/research/"}},"downloads":0},"search_terms":["free","total","prostate","specific","antigen","benign","prostate","hyperplasia","prostate","cancer","naz","ahmad","ghafoor","butt","akhtar","naz ahmad"],"keywords":["benign hyperplasia","free psa","prostate cancer","prostate specific antigen (psa)"],"authorIDs":["uBktm5eDqAhE5NdWa"],"dataSources":["dAJfw83AXweR2io6m","ya2CyA73rpZseyrZ8","JnyAdS67Rhkx3LrTM","2252seNhipfTmjEBQ"]}